Myriad Genetics (MYGN) Cash from Investing Activities (2009 - 2026)
Myriad Genetics (MYGN) reported Cash from Investing Activities of -$6.5 million for Q1 2026, up 21.69% year-over-year from -$5.3 million in Q1 2025, and down 8.33% quarter-over-quarter from -$6.0 million in Q4 2025.
Myriad Genetics (MYGN) Cash from Investing Activities (2009 - 2026) Analysis & Trends
Myriad Genetics (MYGN) has 18 years of Cash from Investing Activities data on file, last reported at -$6.5 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$6.5 million, up 21.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$25.6 million (down 95.42% YoY), and the FY2025 annual result was -$27.4 million, down 130.25% from the prior year.
- Cash from Investing Activities fell to -$6.5 million in Q1 2026 per MYGN's latest filing, from -$6.0 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $34.6 million in Q1 2023 and troughed at -$41.3 million in Q1 2022.
- A 5-year average of -$5.4 million and a median of -$6.4 million in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities plunged 1190.91% in 2022, then surged 400.0% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at -$35.6 million in 2022, then surged by 66.29% to -$12.0 million in 2023, then jumped by 50.83% to -$5.9 million in 2024, then decreased by 1.69% to -$6.0 million in 2025, then declined by 8.33% to -$6.5 million in 2026.
- Business Quant data shows MYGN's Cash from Investing Activities at -$6.5 million in Q1 2026, -$6.0 million in Q4 2025, and -$6.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 30,010.71 Bn | 30,010.25 Bn | 1.11 Bn | 95.00 Mn |
| 2 | Thermo Fisher Scientific | 179.46 Bn | 176.21 Bn | 7.74 Bn | -8.96 Bn |
| 3 | Danaher | 130.33 Bn | 124.64 Bn | 3.59 Bn | -249.00 Mn |
| 4 | Idexx Laboratories | 44.44 Bn | 44.24 Bn | 722.74 Mn | -33.54 Mn |
| 5 | Agilent Technologies | 37.27 Bn | 35.46 Bn | 990.00 Mn | -77.00 Mn |
| 6 | Iqvia Holdings | 30.70 Bn | 28.73 Bn | 1.36 Bn | -196.00 Mn |
| 7 | Natera | 30.59 Bn | 29.49 Bn | 696.04 Mn | -32.14 Mn |
| 8 | Illumina | 24.86 Bn | 23.71 Bn | 721.00 Mn | -366.00 Mn |
| 9 | Mettler Toledo International | 23.06 Bn | 23.00 Bn | 555.82 Mn | -31.35 Mn |
| 10 | Myriad Genetics | 414.15 Mn | 289.75 Mn | 137.60 Mn | -6.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.50 Mn |
| Mar 31, 2026 | -6.50 Mn |
| Dec 31, 2025 | -6.00 Mn |
| Dec 31, 2025 | -6.00 Mn |
| Sep 30, 2025 | -6.20 Mn |
| Sep 30, 2025 | -6.20 Mn |
| Jun 30, 2025 | -6.90 Mn |
| Jun 30, 2025 | -6.90 Mn |
| Mar 31, 2025 | -8.30 Mn |
| Mar 31, 2025 | -8.30 Mn |
| Dec 31, 2024 | -5.90 Mn |
| Dec 31, 2024 | -5.90 Mn |
| Sep 30, 2024 | 7.50 Mn |
| Sep 30, 2024 | 7.50 Mn |
| Jun 30, 2024 | -6.40 Mn |
| Jun 30, 2024 | -6.40 Mn |
| Mar 31, 2024 | -7.10 Mn |
| Mar 31, 2024 | -7.10 Mn |
| Dec 31, 2023 | -12.00 Mn |
| Dec 31, 2023 | -12.00 Mn |